var data={"title":"Epinephrine (adrenaline) (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Epinephrine (adrenaline) (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791141?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=epinephrine-adrenaline-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Epinephrine (adrenaline) (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=epinephrine-adrenaline-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Epinephrine (adrenaline) (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50306669\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pfizer Extended Expiration Dates for Emergency Syringe Shortages</span>\n      <span class=\"collapsible-date\">- updated November 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has alerted health care providers of extended expiration dates for certain injectable drug products manufactured by Hospira (a Pfizer company) which may be used beyond the labeled expiration dates to assist with the ongoing critical shortages of injectable drugs used in critical care. Select lot numbers of atropine sulfate injection, dextrose 50%, epinephrine injection, and sodium bicarbonate are eligible for use beyond the labeled expiration date if they have been and will continue to be stored according to the labeled conditions<b>. </b></p>\n        <p style=\"text-indent:0em;\">Further information, including specific products, lot numbers, and extended expiration dates, may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPGtnB1wPEGG5AqBctyC78FXNni9GZNAqH+dg03OunIQVFis/VBQ2KMfj5sKJ1X0d3K8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=105602\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm</a><b>.</b></p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623785\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adrenaclick [DSC];</li>\n      <li>Adrenalin;</li>\n      <li>Adyphren;</li>\n      <li>Adyphren Amp;</li>\n      <li>Adyphren Amp II;</li>\n      <li>Adyphren II;</li>\n      <li>Auvi-Q;</li>\n      <li>Epinephrinesnap-v;</li>\n      <li>EpiPen 2-Pak;</li>\n      <li>EpiPen Jr 2-Pak;</li>\n      <li>EPIsnap;</li>\n      <li>EPY II [DSC];</li>\n      <li>EPY [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623786\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adrenalin;</li>\n      <li>Allerject;</li>\n      <li>Anapen;</li>\n      <li>Anapen Junior;</li>\n      <li>EpiPen;</li>\n      <li>EpiPen Jr;</li>\n      <li>Twinject</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623791\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha-/Beta- Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623834\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: As of May 1, 2016, ratio expressions of epinephrine concentrations are prohibited on drug labels. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory until replaced by products with revised labeling. Therefore, the ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (ISMP 2015).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute severe asthma unresponsive to inhaled beta-agonist (off-label use):</b> IM, SubQ: 0.01 mg/kg divided into 3 doses of approximately 0.3 to 0.5 mg every 20 minutes; the <b>1 mg/mL</b> concentration is recommended (AHA [Vanden Hoek 2010]; Cydulka 2016; Shah 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asystole/pulseless arrest, pulseless VT/VF (ACLS [Neumar 2010]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV, Intraosseous:</i> 1 mg every 3 to 5 minutes until return of spontaneous circulation; if this approach fails, higher doses of epinephrine (up to 0.2 mg/kg) have been used for treatment of specific problems (eg, beta-blocker or calcium channel blocker overdose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: </b>High IV dose epinephrine (ie, &gt;1 mg per dose) has not been shown to improve survival or neurological outcomes as compared to standard dose epinephrine and is not recommended (ACLS [Neumar 2010]; ACLS [Neumar 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endotracheal:</i> 2 to 2.5 mg every 3 to 5 minutes until IV/intraosseous access established or return of spontaneous circulation; dilute in 5 to 10 mL NS or sterile water. <b>Note:</b> Absorption may be greater with sterile water (Naganobu 2000). May cause false-negative reading with exhaled CO<sub>2</sub> detectors; use second method to confirm tube placement if CO<sub>2</sub> is not detected (ACLS [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bradycardia (symptomatic; unresponsive to atropine or pacing):</b> <i>IV infusion:</i> 2 to 10 mcg/minute <b>or</b> 0.1 to 0.5 mcg/kg/minute (7 to 35 mcg/minute in a 70 kg patient); titrate to desired effect (ACLS [Neumar 2010]; AHA [Peberdy 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypersensitivity reaction (eg, anaphylaxis): </b> <b>Note:</b> SubQ administration results in slower absorption and is less reliable. IM administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (AHA [Vanden Hoek 2010]; WAO [Kemp 2008]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM (preferred), SubQ:</i> 0.2 to 0.5 mg using the <b>1 mg/mL</b> solution every 5 to 15 minutes in the absence of clinical improvement (AAAAI [Lieberman 2015]; AHA [Vanden Hoek 2010]; WAO [Kemp 2008]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Slow IV bolus: 0.1 mg using the <b>0.1 mg/mL</b> solution (further diluted in 10 mL of NS) administered over 5 to 10 minutes (Barach 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: May initiate with an infusion at 2 to 15 mcg/minute (with crystalloid administration) (AAAAI [Lieberman 2015]; AHA [Vanden Hoek 2010]; Brown 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> In general, IV administration should only be done in patients who are unresponsive or profoundly hypotensive who have failed to respond to IV fluid replacement and several epinephrine injections (WAO [Kemp 2008]). If the patient is in cardiopulmonary arrest, use of higher IV/IO push doses (ie, 1 mg every 3 to 5 minutes) should be employed or appropriate endotracheal doses administered if an advanced airway is in place (AAAAI [Lieberman 2015]; AHA [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Self-administration following severe allergic reactions (eg, insect stings, food):</i> <b>Note:</b> The World Health Organization (WHO) and Anaphylaxis Canada recommend the availability of one dose for every 10 to 20 minutes of travel time to a medical emergency facility. If anaphylactic symptoms persist after first dose, may repeat dose in 5 to 15 minutes (AHA [Vanden Hoek 2010]); more than 2 sequential doses should only be administered under direct medical supervision.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adrenaclick: IM, SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated using an additional Adrenaclick injector</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Allerject [Canadian product]: IM: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated using an additional Allerject injector</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Auvi-Q: IM, SubQ: Weight &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">EpiPen: IM, SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated using an additional EpiPen</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Symjepi: IM, SubQ: Weight &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Twinject [Canadian product]: IM, SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5 to 15 minutes using the same device after partial disassembly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension/shock:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> Septic shock: IV infusion: Initial: 0.05 to 2 mcg/kg/minute (3.5 to 140 mcg/minute in a 70 kg patient); titrate to desired mean arterial pressure (MAP). May adjust dose every 10 to 15 minutes by 0.05 to 0.2 mcg/kg/minute to achieve desired blood pressure goal. After hemodynamic stabilization, may wean incrementally every 30 minutes over 12 to 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>American Heart Association recommendation:</i> Severe and fluid resistant (off-label dosing): IV infusion: Initial: 0.1 to 0.5 mcg/kg/minute (7 to 35 mcg/minute in a 70 kg patient); titrate to desired response (AHA [Peberdy 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cardiogenic shock (off-label dose):</i> IV infusion: 0.01 to 0.5 mcg/kg/minute (AHA [van Diepen 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mydriasis during intraocular surgery, induction and maintenance (product specific):</b> Intraocular: Must dilute 1 mL of a 1 mg/mL single-use solution to a concentration of 1 to 10 <b>mcg</b>/mL prior to intraocular use: May use as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye) with a bolus dose of 0.1 mL of a 2.5 to 10 <b>mcg</b>/mL dilution. <b>Note:</b> Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information (ISMP 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623833\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=epinephrine-adrenaline-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Epinephrine (adrenaline) (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: As of May 1, 2016, ratio expressions of epinephrine concentrations are prohibited on drug labels. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory until replaced by products with revised labeling. Therefore, the ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (ISMP 2015).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Asystole/pulseless arrest, pulseless VT/VF (after failed defibrillation attempts) (PALS [Kleinman 2010]):</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV, Intraosseous:</i> 0.01 mg/kg (0.1 mL/kg of <b>0.1 mg/mL</b> solution) (maximum single dose: 1 mg) every 3 to 5 minutes until return of spontaneous circulation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endotracheal:</i> 0.1 mg/kg (0.1 mL/kg of <b>1 mg/mL</b> solution) (maximum single dose: 2.5 mg) every 3 to 5 minutes until IV/Intraosseous access established or return of spontaneous circulation. <b>Note:</b> Recent clinical studies suggest that lower epinephrine concentrations delivered by endotracheal administration may produce transient beta<sub>2</sub>-adrenergic effects which may be detrimental (eg, hypotension, lower coronary artery perfusion pressure). IV and Intraosseous are the preferred methods of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bradycardia (symptomatic; unresponsive to atropine or pacing) (PALS [Kleinman 2010]):</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV, Intraosseous:</i> 0.01 mg/kg (0.1 mL/kg of <b>0.1 mg/mL</b> solution) (maximum single dose: 1 mg) every 3 to 5 minutes as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endotracheal:</i> 0.1 mg/kg (0.1 mL/kg of <b>1 mg/mL</b> solution) (maximum single dose: 2.5 mg) every 3 to 5 minutes as needed until IV/Intraosseous access established. <b>Note:</b> Recent clinical studies suggest that lower epinephrine concentrations delivered by endotracheal administration may produce transient beta<sub>2</sub>-adrenergic effects which may be detrimental (eg, hypotension, lower coronary artery perfusion pressure). IV and Intraosseous are the preferred methods of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiac output maintenance/stabilization, postresuscitation (PALS [Kleinman 2010]):</b> Infants, Children, and Adolescents: Continuous IV/Intraosseous infusion: 0.1 to 1 mcg/kg/minute; doses &lt;0.3 mcg/kg/minute generally produce beta-adrenergic effects and higher doses (&gt;0.3 mcg/kg/minute) generally produce alpha-adrenergic vasoconstriction; titrate dosage to desired effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypersensitivity reaction (eg, anaphylaxis):</b> Infants, Children, and Adolescents: <b>Note:</b> SubQ administration results in slower absorption and is less reliable. IM administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (AAAAI [Lieberman 2015]; Campbell 2014; Simons 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM (preferred), SubQ:</i> 0.01 mg/kg (0.01 mL/kg of <b>1 mg/mL</b> solution) not to exceed 0.3 to 0.5 mg every 5 to 15 minutes (Hegenbarth 2008; Simons 2011; Simons 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Self-administration following severe allergic reactions (eg, insect stings, food):</i> <b>Note: </b>If anaphylactic symptoms persist after first dose, may repeat dose in 5 to 15 minutes (Simons 2011); more than 2 sequential doses should only be administered under direct medical supervision.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adrenaclick: IM, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 15 to 29 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated using an additional Adrenaclick injector</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated using an additional Adrenaclick injector</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Allerject [Canadian product]: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 15 to 29 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated using an additional Allerject injector</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated using an additional Allerject injector</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Auvi-Q: IM, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 7.5 to 14 kg: 0.1 mg; if anaphylactic symptoms persist, dose may be repeated</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 15 to 29 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">EpiPen Jr: IM, SubQ: Children 15 to 29 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated using an additional EpiPen Jr</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">EpiPen: IM, SubQ: Children &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated using an additional EpiPen</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Symjepi: IM, SubQ: Children and Adolescents &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Twinject [Canadian product]: IM, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 15 to 29 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated in 5 to 15 minutes using the same device after partial disassembly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5 to 15 minutes using the same device after partial disassembly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate auto-injector dose:</i> IM (Sicherer 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 10 to 25 kg: 0.15 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;25 kg: 0.3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension/shock, fluid-resistant (off-label use):</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: 0.1 to 1 mcg/kg/minute; rates &gt;0.3 mcg/kg/minute associated with vasopressor activity; doses up to 5 mcg/kg/minute may rarely be necessary; for fluid-resistant shock, may be combined with inotropic support (ACCM [Davis 2017]; Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 0.01 mg/kg (0.01 mL/kg of 1 mg/mL solution) (maximum single dose: 0.5 mg) every 20 minutes for 3 doses (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mydriasis during intraocular surgery, induction and maintenance (product specific):</b> Infants, Children, and Adolescents: Intraocular: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623835\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623836\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623837\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623858\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Device, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EpiPen Jr 2-Pak: 0.15 mg/0.3 mL (2 ea) [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adyphren: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adyphren Amp: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adyphren Amp II: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adyphren II: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epinephrinesnap-v: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EPIsnap: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EPY: 1 mg/mL [DSC] [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EPY II: 1 mg/mL [DSC] [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adrenalin: 30 mg/30 mL (30 mL) [contains chlorobutanol (chlorobutol), disodium edta, sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (1 mL); 30 mg/30 mL (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adrenalin: 1 mg/mL (1 mL) [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adrenaclick: 0.15 mg/0.15 mL (2 ea [DSC]); 0.3 mg/0.3 mL (2 ea [DSC]) [latex free; contains chlorobutanol (chlorobutol), sodium bisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Auvi-Q: 0.15 mg/0.15 mL (2 ea); 0.3 mg/0.3 mL (2 ea) [contains sodium bisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EpiPen 2-Pak: 0.3 mg/0.3 mL (2 ea) [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.15 mg/0.3 mL (1 ea, 2 ea); 0.15 mg/0.15 mL (1 ea [DSC], 2 ea); 0.3 mg/0.3 mL (1 ea, 2 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mcg/10 mL in NaCl 0.9% (10 mL); 200 mcg/10 mL in NaCl 0.9% (10 mL); 50 mcg/5 mL in NaCl 0.9% (5 mL); 500 mcg/10 mL in NaCl 0.9% (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623789\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50287478\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AUVI-Q 0.1 mg: FDA approved November 2017; availability anticipated in the first half of 2018. Consult prescribing information for additional information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Symjepi: FDA approved June 2017; anticipated availability currently undetermined</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623839\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Epinephrine solutions for injection can be administered IM, intraosseous, endotracheally, IV, or SubQ. <b>Note:</b> Adrenaclick, Allerject [Canadian product], Auvi-Q, EpiPen, EpiPen Jr, and Symjepi contain a single, fixed-dose of epinephrine and may only be administered IM (preferred) or SubQ. Twinject Auto-Injectors [Canadian product] contain two doses; the first fixed-dose is available for auto-injection; the second dose is available for manual injection following partial disassembly of device.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">IV: When administering as a continuous infusion, central line administration is preferred. IV infusions require an infusion pump. If central line not available, as a temporary measure, may administer through a large vein. Avoid use of ankle veins (due to potential for gangrene), leg veins in elderly patients, or leg veins in those suffering from occlusive vascular diseases (eg, diabetic endarteritis, Buerger disease, arteriosclerosis, atherosclerosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative antidote). Apply dry warm compresses (Hurst 2004; Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Phentolamine:</i> Dilute 5 to 10 mg in 10 to 20 mL NS and administer into extravasation site as soon as possible after extravasation; may readminister if patient remains symptomatic (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternatives to phentolamine:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nitroglycerin topical 2% ointment (based on limited data):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Adults:</i> Apply a 1-inch strip to the site of ischemia; may repeat every 8 hours as necessary (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Pediatrics:</i> Apply 4 mm/kg as a thin ribbon to the site of ischemia; may repeat after 8 hours if needed (Wong 1992) <b>or</b> apply a 1-inch strip to the site of ischemia; may repeat every 8 hours as necessary (Denkler 1989; Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Terbutaline (based on limited case reports): Infiltrate extravasation area using a solution of terbutaline 1 mg diluted in 10 mL NS (large extravasation site; administration volume varied from 3 to 10 mL) <b>or</b> 1 mg diluted in 1 mL NS (small/distal extravasation site; administration volume varied from 0.5 to 1 mL) (Reynolds 2014; Stier 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subcutaneous: SubQ administration results in slower absorption and is less reliable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: IM administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (AHA [Vanden Hoek 2010]; WAO [Kemp 2008]). Administer through clothing if necessary. Before administering to a child, immobilize leg to prevent laceration or other injury and consider restraining children who are likely to move during administration. Although the manufacturers of auto-injectors recommend varying lengths of time for holding the device in the thigh (range: 2 to 10 seconds), longer times have occasionally resulted in injury. For all devices, the needle should remain in the thigh for the least amount of time as possible. With nearly every device, the full dose is delivered within 3 seconds. For EpiPen, holding the device against the leg followed by removing the cap and then compressing has been described for easier administration. Never reinsert needles (Baker 2011; Brown 2016; Kr&auml;nke 2012; Lieberman 2011). Do not administer repeated injections at the same site. Do not inject into the buttocks or into digits, hands, or feet. Adrenaclick, Adrenalin, Allerject [Canadian product], Auvi-Q, EpiPen, EpiPen Jr, Symjepi, and Twinject [Canadian product] should only be injected into the anterolateral aspect of the thigh.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Obesity:</i> In overweight or obese children, because skin surface to muscle depth is greater in the upper half of the thigh, administration into the lower half of the thigh may be preferred. In very obese children, injection into the calf will provide an even greater chance of intramuscular administration (Arkwright 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intraocular (product specific): May administer diluted solution (concentration: 1 to 10 <b>mcg</b>/mL) as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye). <b>Note:</b> Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information. Appropriate products should have mydriasis during intraocular surgery as an approved indication and should not contain any sulfites or preservatives (ISMP 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endotracheal (cardiac arrest): Dilute in NS or sterile water. Absorption may be greater with sterile water (Naganobu 2000). Stop compressions, spray drug quickly down tube. Follow immediately with several quick insufflations and continue chest compressions. May cause false-negative reading with exhaled CO<sub>2</sub> detectors; use second method to confirm tube placement if CO<sub>2</sub> is not detected (ACLS [Neumar 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623849\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 1 mg in 250 mL (concentration: 4 <b>mcg</b>/mL) <b>or</b> 4 mg in 250 mL (concentration: 16 <b>mcg</b>/mL) of D<sub>5</sub>W or NS; 1 mg in 1,000 mL (concentration: 1 <b>mcg</b>/mL) in D<sub>5</sub>W, D<sub>5</sub>NS, or NS.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623848\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 16 <b>mcg</b>/mL, 32 <b>mcg</b>/mL, or 64 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623795\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypersensitivity:</b> Treatment of type I allergic reactions, including anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension/shock:</b> Treatment of hypotension associated with septic shock in adults (increase mean arterial blood pressure).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Guideline recommendations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cardiogenic shock:</i> The 2017 American Heart Association (AHA) scientific statement for the Contemporary Management of Cardiogenic Shock recommends epinephrine, if needed, be considered for initial vasoactive management of cardiogenic shock in patients with bradycardia or evidence of end organ hypoperfusion but systolic blood pressure &gt;90 mm Hg. Norepinephrine is the vasopressor of choice in cases of shock with severe hypotension (AHA [van Diepen 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Septic shock:</i> The Surviving Sepsis Campaign guidelines recommend epinephrine, if needed, be used in addition to norepinephrine (the preferred first-line single-agent vasopressor) for the intent of raising mean arterial pressure (MAP) to target (Rhodes 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mydriasis during intraocular surgery (product specific):</b> Induction and maintenance of mydriasis during intraocular surgery. <b>Note:</b> Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623796\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute severe asthma unresponsive to inhaled beta-agonist; Asystole/pulseless arrest, ventricular fibrillation, or pulseless ventricular tachycardia; Bradycardia unresponsive to atropine or pacing; Hypotension/shock unresponsive to volume resuscitation; Inotropic support</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623780\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EPINEPHrine may be confused with ePHEDrine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epifrin may be confused with ephedrine, EpiPen</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Medication errors have occurred due to confusion with epinephrine products expressed as ratio strengths (eg, 1:1000 vs 1:10,000). </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epinephrine 1:1000 = 1 mg/mL and is most commonly used IM</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epinephrine 1:10,000 = 0.1 mg/mL and is used IV</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Medication errors have occurred when topical epinephrine 1 mg/mL (1:1000) has been inadvertently injected. Vials of injectable and topical epinephrine look very similar. Epinephrine should always be appropriately labeled with the intended administration. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">EpiPen [US, Canada, and multiple international markets] may be confused with Epigen brand name for glycyrrhizinic acid [Argentina, Mexico, Russia] and Epopen brand name for epoetin alfa [Spain] and Epigent brand name for gentamicin [multiple international markets] </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623807\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, cardiac arrhythmia, cardiomyopathy (stress), cerebrovascular accident, chest pain, hypertension, ischemic heart disease, limb ischemia, localized blanching, myocardial infarction, palpitations, supraventricular tachycardia, tachyarrhythmia, tachycardia, vasoconstriction, ventricular arrhythmia, ventricular ectopy, ventricular fibrillation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, apprehension, disorientation, dizziness, drowsiness, exacerbation of Parkinson disease, excitability, headache, memory impairment, nervousness, panic, paresthesia, psychomotor agitation, restlessness, tingling sensation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, gangrene of skin or other tissue (at injection site), pallor, piloerection, skin necrosis (with extravasation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia, hypoglycemia, hypokalemia, increased serum glucose (transient), insulin resistance, lactic acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemorrhage (CNS)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site tissue necrosis (including necrotizing fasciitis and myonecrosis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, pulmonary edema, rales</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623804\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no absolute contraindications to the use of injectable epinephrine (including Adrenaclick, Auvi-Q, EpiPen, EpiPen Jr, Symjepi, Allerject [Canadian product], and Twinject [Canadian product]) in a life-threatening situation. Some products include the following contraindications: Hypersensitivity to sympathomimetic amines; general anesthesia with halogenated hydrocarbons (eg, halothane) or cyclopropane; narrow angle glaucoma; nonanaphylactic shock; in combination with local anesthesia of certain areas such as fingers, toes, and ears; use in situations where vasopressors may be contraindicated (eg, thyrotoxicosis, diabetes, in obstetrics when maternal blood pressure is in excess of 130/80 mm Hg and in hypertension and other cardiovascular disorders).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injectable solution (Adrenalin, Epinephrine injection, USP): There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623805\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac effects: May precipitate or aggravate angina pectoris or induce cardiac arrhythmias; use with caution especially in patients with cardiac disease or those receiving drugs that sensitize the myocardium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: IV administration: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary edema: Due to peripheral constriction and cardiac stimulation, pulmonary edema may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: Due to renal blood vessel constriction, decreased urine output may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular diseases (eg, arrhythmias, cerebrovascular disease, coronary artery disease, heart disease, hypertension).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may transiently increase blood glucose levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypovolemia: Correct blood volume depletion before administering any vasopressor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; psychomotor agitation or temporary worsening of symptoms may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with caution in patients with pheochromocytoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Use with caution in patients with thyroid disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Lacerations, bent needles, and embedded needles have been reported in young children who are uncooperative during injection for hypersensitivity reaction. To minimize risk, hold the child's leg firmly in place and limit movement prior to and during injection. Although the manufacturers of auto-injectors recommend varying lengths of time for holding the device in the thigh (range: 2 to 10 seconds), longer times have occasionally resulted in injury. For all devices, the needle should remain in the thigh for the least amount of time as possible (~3 seconds) (Brown 2016) (also see Administration: IM).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental injection: Accidental injection into digits, hands, or feet may result in local reactions including injection-site pallor, coldness, and hypoesthesia or injury resulting in bruising, bleeding, discoloration, erythema, or skeletal injury. Patient should seek immediate medical attention if this occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraocular use: Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information prior to selecting a product. Appropriate products should have an indication for induction and maintenance of mydriasis during intraocular surgery and should not contain any sulfites or preservatives (ISMP 2017). Prior to intraocular use of an appropriate product, must dilute single-use 1 mg/mL (1 mL) solution to a concentration of 1 <b>mcg</b>/mL to 10 <b>mcg</b>/mL. Corneal endothelial damage has occurred when products containing sodium bisulfite have been used undiluted; therefore, dilution is advised prior to any intraocular use. In addition, products containing chlorobutanol must also not be used intraocularly (may be harmful to corneal endothelium).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Rapid IV administration may cause death from cerebrovascular hemorrhage or cardiac arrhythmias. However, rapid IV administration during pulseless arrest is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Some products may contain sulfites as preservatives. The presence of sulfites in some products should not deter administration during a serious allergic or other emergency situation even if the patient is sulfite-sensitive.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Hypersensitivity reactions: Do not inject into the buttock; may not effectively treat anaphylaxis and has been associated with Clostridial infections (gas gangrene). Serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported rarely at the injection site. Cleansing skin with alcohol may reduce bacteria at the injection site, but alcohol cleansing does not kill <i>Clostridium</i> spores. Preferred injection site is anterolateral aspect of the thigh. Do not administer repeated injections at the same site (tissue necrosis may occur). Monitor for signs/symptoms of injection-site infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623814\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of COMT</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623811\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105602&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">COMT Inhibitors: May decrease the metabolism of COMT Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic). Management: Administer epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower than normal doses of epinephrine and monitor for the development of cardiac arrhythmias.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: EPINEPHrine (Systemic) may enhance the hypotensive effect of Lurasidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic). Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Management: Avoid, if possible, the use of direct-acting alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623800\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623801\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Epinephrine crosses the placenta (Sandler 1964). Uterine vasoconstriction, decreased uterine blood flow, and fetal anoxia may occur. Epinephrine is recommended for the treatment of anaphylaxis in pregnant women. Specific dosing is not available; use with caution and monitor hemodynamic response (Hepner 2013). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015). Although epinephrine injection may be used for asthma exacerbations in pregnancy, systemic therapy has not been proven to be better than use of preferred inhaled agents (NAEPP 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623802\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if epinephrine is present in breast milk. The manufacturer recommends that caution be exercised when administering epinephrine to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623850\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure (invasive blood pressure monitoring and central venous pressure monitoring recommended while receiving continuous infusion); monitor site of infusion for blanching/extravasation; continuous cardiac monitoring required during continuous infusion. If using to treat hypotension, assess intravascular volume prior to and during therapy; support as needed.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623822\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates alpha-, beta<sub>1</sub>-, and beta<sub>2</sub>-adrenergic receptors resulting in relaxation of smooth muscle of the bronchial tree, cardiac stimulation (increasing myocardial oxygen consumption), and dilation of skeletal muscle vasculature; small doses can cause vasodilation via beta<sub>2</sub>-vascular receptors; large doses may produce constriction of skeletal and vascular smooth muscle</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623824\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Bronchodilation: SubQ: ~5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Orally ingested doses are rapidly metabolized in GI tract and liver; pharmacologically active concentrations are not achieved</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Does not cross blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Taken up into the adrenergic neuron and metabolized by monoamine oxidase and catechol-o-methyltransferase; circulating drug hepatically metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: &lt;5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as inactive metabolites, metanephrine, and sulfate and hydroxy derivatives of mandelic acid, small amounts as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623860\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Adyphren Amp II Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $85.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Adyphren Amp Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $85.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Adyphren II Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $85.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Adyphren Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $85.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Epinephrinesnap-v Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $180.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (EPIsnap Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $156.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Adrenalin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $17.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/30 mL (30 mL): $143.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (EPINEPHrine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/30 mL (30 mL): $70.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (EPINEPHrine PF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $2.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Auvi-Q Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15 mg/0.15 mL (2): $5,880.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/0.3 mL (2): $5,880.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (EPINEPHrine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15 mg/0.15 mL (2): $494.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15 mg/0.3 mL (1): $187.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/0.3 mL (2): $375.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (EpiPen 2-Pak Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/0.3 mL (2): $730.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (EpiPen Jr 2-Pak Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15 mg/0.3 mL (2): $730.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (EPINEPHrine HCl-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200MCG/10ML 0.9% (10 mL): $6.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (EPINEPHrine HCl-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MCG/5ML 0.9% (5 mL): $10.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100MCG/10ML 0.9% (10 mL): $7.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500MCG/10ML 0.9% (10 mL): $7.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (EPINEPHrine PF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/10 mL (10 mL): $5.47</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45855086\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adreject (CL);</li>\n      <li>Adreject Jr (CL);</li>\n      <li>Adrena (IN);</li>\n      <li>Adrenalin (BG, FI, TR);</li>\n      <li>Adrenalina (IT);</li>\n      <li>Adrenalina Sintetica (CH);</li>\n      <li>Adrenaline (RU);</li>\n      <li>Adrenaline Aguettant (FR);</li>\n      <li>Adrenalini Bitarticas (ID);</li>\n      <li>Adrenin (PH);</li>\n      <li>Ana-Guard (ZA);</li>\n      <li>Anapen (AT, CH, CY, CZ, DE, DK, EE, ES, FR, GR, HU, IE, LT, LU, LV, NL, PL, PT, SE, SG, SI);</li>\n      <li>Drenalin (BR);</li>\n      <li>Efrinalin (BR);</li>\n      <li>Ephedrix (PH);</li>\n      <li>Epifrin (BR);</li>\n      <li>Epifrina (CL, EC);</li>\n      <li>Epipen (AR, AT, AU, BB, BE, BG, CH, CZ, DK, EE, FI, FR, GB, GR, HK, HU, IE, IL, IS, LT, MT, NL, NO, NZ, PL, PT, RO, SE, SG, SI, SK, ZA);</li>\n      <li>Epipen Jr (AU);</li>\n      <li>Epipen Junior (BG, CZ, FI, GB, HK, IL, IS, MT, NL, NO, NZ, SE, SG, SK, TH);</li>\n      <li>Epix (PH);</li>\n      <li>Eppy (ZA);</li>\n      <li>Jext (AT, BE, CH, DK, ES, FI, FR, GB, NL, NO, SE, SK);</li>\n      <li>Phinev (ID);</li>\n      <li>Suprarenin (AT, DE);</li>\n      <li>Vascon (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2005, 112(24 Suppl): 1-211.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adrenaclick (epinephrine) [prescribing information]. Horsham, PA; Amedra; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adrenalin (epinephrine) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceuticals; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allerject (epinephrine) [product monograph]. Laval, Quebec: Sanofi-aventis Canada Inc; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Auvi-Q (epinephrine) [prescribing information]. Richmond, VA: Kaleo Inc.; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Annane D, Vignon P, Renault A, et al, &ldquo;Norepinephrine Plus Dobutamine Versus Epinephrine Alone for Management of Septic Shock: A Randomized Trial,&rdquo; <i>Lancet</i>, 2007, 370(9588):676-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/17720019/pubmed\" target=\"_blank\" id=\"17720019\">17720019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arkwright P, Wright N, Bewick D, &ldquo;Anatomical and Anthropometric Determinants of Intramuscular versus Subcutaneous Administration in Children With Epinephrine Auto-injectors,&rdquo; <i>J Allergy Clin Immunol</i>, 2013, 131(2):AB199.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21875542\"></a>Baker TW, Webber CM, Stolfi A, Gonzalez-Reyes E. The TEN study: time epinephrine needs to reach muscle. <i>Ann Allergy Asthma Immunol</i>. 2011;107(3):235-238. doi: 10.1016/j.anai.2011.06.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/21875542/pubmed\" target=\"_blank\" id=\"21875542\">21875542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barach EM, Nowak RM, Lee TG, Tomlanovich MC. Epinephrine for treatment of anaphylactic shock. JAMA, 1984, 251 (16): 2118-2122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/6708262/pubmed\" target=\"_blank\" id=\"6708262\">6708262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo; <i>Crit Care Med</i>, 2009, 37(2):666-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/19325359/pubmed\" target=\"_blank\" id=\"19325359\">19325359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26452720\"></a>Brown JC, Tuuri RE, Akhter S, et al. Lacerations and embedded needles caused by epinephrine autoinjector use in children. <i>Ann Emerg Med</i>. 2016;67(3):307-315.e8. doi: 10.1016/j.annemergmed.2015.07.011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/26452720/pubmed\" target=\"_blank\" id=\"26452720\">26452720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown SG, Blackman KE, Stenlake V, et al, &quot;Insect Sting Anaphylaxis; Prospective Evaluation of Treatment With Intravenous Adrenaline and Volume Resuscitation,&quot; <i>Emerg Med J</i>, 2004, 21(2):149-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/14988337/pubmed\" target=\"_blank\" id=\"14988337\">14988337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campbell RL, Li JT, Nicklas RA, et al. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. <i>Ann Allergy Asthma Immunol.</i> 2014;113(6):599-608.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cydulka R, Davison R, Grammer L, et al, &ldquo;The Use of Epinephrine in the Treatment of Older Adult Asthmatics,&rdquo; <i>Ann Emerg Med</i>, 1988, 17(4):322-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/3354935/pubmed\" target=\"_blank\" id=\"3354935\">3354935</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. <i>Crit Care Med</i>. 2017;45(6):1061-1093.doi: 10.1097/CCM.0000000000002425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/28509730/pubmed\" target=\"_blank\" id=\"28509730\">28509730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis C and Wax P, &ldquo;Subcutaneous Epinephrine O.D. in a Child Resulting in Dysrhythmias and Myocardial Ischemia,&rdquo; <i>Vet Hum Toxicol</i>, 1994, 36:367.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Denkler KA and Cohen BE, &ldquo;Reversal of Dopamine Extravasation Injury With Topical Nitroglycerin Ointment,&rdquo; <i>Plast Reconstr Surg</i>, 1989, 84(5):811-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/2510208/pubmed\" target=\"_blank\" id=\"2510208\">2510208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epinephrine Injection [prescribing information]. Largo, FL: Belcher Pharmaceuticals; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epinephrine injection (auto-injector) [prescribing information]. Lineage Therapeutics Inc.; Horsham, PA: May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EpiPen/EpiPen Jr (epinephrine) [prescribing information]. Morgantown, WV: Mylan Specialty LP; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EpiPen/EpiPen Jr (epinephrine) [prescribing information]. Morgantown, WV: Mylan Specialty LP; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EpiPen/EpiPen Jr (epinephrine) [prescribing information]. Morgantown, WV: Mylan Specialty LP; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo; <i>Clinical Practice Guidelines</i>, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goring-Morris J and Russell IF, &ldquo;A Randomized Comparison of 0.5% Bupivacaine With a Lidocaine/Epinephrine/Fentanyl Mixture for Epidural Top-up for Emergency Caesarean Section After &ldquo;Low Dose&rdquo; Epidural for Labour,&rdquo; <i>Int J Obstet Anesth</i>, 2006, 15(2):109-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/16488138/pubmed\" target=\"_blank\" id=\"16488138\">16488138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gueugniaud PY, David JS, Chanzy E, et al, &ldquo;Vasopressin and Epinephrine vs. Epinephrine Alone in Cardiopulmonary Resuscitation,&rdquo; <i>N Engl J Med</i>, 2008, 359(1):21-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/18596271/pubmed\" target=\"_blank\" id=\"18596271\">18596271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18245435\"></a>Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hepner DL, Castells M, Mouton-Faivre C, Dewachter P. Anaphylaxis in the clinical setting of obstetric anesthesia: a literature review. <i>Anesth Analg</i>. 2013;117(6):1357-1367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/24257386 /pubmed\" target=\"_blank\" id=\"24257386 \">24257386 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollenberg SM, Ahrens TS, Annane D, et al, &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,&rdquo; <i>Crit Care Med</i>, 2004, 32(9):1928-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/15343024/pubmed\" target=\"_blank\" id=\"15343024\">15343024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S and McMillan M, &ldquo;Innovative Solutions in Critical Care Units: Extravasation Guidelines,&rdquo; <i>Dimens Crit Care Nurs</i>, 2004, 23(3):125-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Illi A, Sundberg S, Ojala-Karlsson P, et al, &ldquo;The Effect of Entacapone on the Disposition and Hemodynamic Effects of Intravenous Isoproterenol and Epinephrine,&rdquo; <i>Clin Pharmacol Ther</i>, 1995, 58(2):221-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/7648772/pubmed\" target=\"_blank\" id=\"7648772\">7648772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices. Farewell to ratio expressions on single entity drug labels. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2015;20(24):2-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/26443610/pubmed\" target=\"_blank\" id=\"26443610\">26443610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kartawiadi L, Vercauteren MP, Van Steenberge AL, et al, &ldquo;Spinal Analgesia During Labor With Low-dose Bupivacaine, Sufentanil, and Epinephrine. A Comparison with Epidural Analgesia,&rdquo; <i>Reg Anesth</i>, 1996, 21(3):191-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/8744659/pubmed\" target=\"_blank\" id=\"8744659\">8744659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kemp SF, Lockey RF, Simons FE, et al, &ldquo;Epinephrine: The Drug of Choice for Anaphylaxis. A Statement of the World Allergy Organization,&rdquo; <i>Allergy</i>, 2008, 63(8):1061-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/18691308/pubmed\" target=\"_blank\" id=\"18691308\">18691308</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein JS, Rich MR, and Yunginger JW, &ldquo;Myocardial Ischemia Without Coronary Artery Disease After Epinephrine Overdose for Insect Sting Reaction,&rdquo; <i>J Allergy Clin Immunol</i>, 1995, 95(2):371.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22594931\"></a>Kr&auml;nke B, Schuster C, Wiednig M, Reiter H. A simple method to improve safety of epinephrine auto-injectors. <i>Pediatr Allergy Immunol</i>. 2012;23(4):399-400. doi: 10.1111/j.1399-3038.2012.01299.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/22594931/pubmed\" target=\"_blank\" id=\"22594931\">22594931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuracheck SC, Rockoff MA Inadvertent Intravenous Administration of Racemic Epinephrine. <i>JAMA.</i> 1984;253(10):1441-1442.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/3968774/pubmed\" target=\"_blank\" id=\"3968774\">3968774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21875535\"></a>Lieberman P. The 10-second rule and other myths about epinephrine and autoinjectors. <i>Ann Allergy Asthma Immunol</i>. 2011;107(3):189-190. doi: 10.1016/j.anai.2011.07.007.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/21875535/pubmed\" target=\"_blank\" id=\"21875535\">21875535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol.</i> 2015;115(5):341-384.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/20692689/pubmed\" target=\"_blank\" id=\"20692689\">20692689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy FT, Manown TJ, Knutson SW, et al, &ldquo;Epinephrine-Induced Lactic Acidosis in the Setting of Status Asthmaticus,&rdquo; <i>South Med J</i>, 1995, 88(5):577-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/7732451/pubmed\" target=\"_blank\" id=\"7732451\">7732451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP). Working Group Report on Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment, Update 2004. NIH Publication No. 05-5236. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; March 2005. <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a>. Accessed February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program, &quot;Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma,&quot; Bethesda, MD, National Institutes of Health, 1997. NIH publication 97-4051.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naganobu K, Hasebe Y, Uchiyama Y, et al, &ldquo;A Comparison of Distilled Water and Normal Saline as Diluents for Endobronchial Administration of Epinephrine in the Dog,&rdquo; <i>Anesth Analg</i>, 2000, 91(2):317-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/10910841/pubmed\" target=\"_blank\" id=\"10910841\">10910841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Shuster M, Callaway CW, et al. Part 1: Executive Summary: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015;132[suppl 2]:S315&ndash;S367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/26472989/pubmed\" target=\"_blank\" id=\"26472989\">26472989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peberdy MA, Callaway CW, Neumar RW, et al, &ldquo;Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):768-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/20956225/pubmed\" target=\"_blank\" id=\"20956225\">20956225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, Maclaren R, Mueller SW, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. DOI: 10.1002/phar.1396<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28101605\"></a>Rhodes A, Evans LE, Alhazzani W,et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russell JA, Walley KR, Singer J, et al, &ldquo;Vasopressin Versus Norepinephrine Infusion in Patients With Septic Shock,&rdquo; <i>N Engl J Med</i>, 2008, 358(9):877-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/18305265/pubmed\" target=\"_blank\" id=\"18305265\">18305265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandler M, Ruthren CR, Wood C. Metabolism of C14-norepinephrine and 14-epinephrine and their transmission across the human placenta. <i>Int J Neuropharmacol</i>. 1964;3:123-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/14334587/pubmed\" target=\"_blank\" id=\"14334587\">14334587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sedlak T, Shufelt C, Iribarren C, et al, &quot;Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval,&quot; <i>Ann Noninvasive Electrocardiol</i>, 2013, 18(4):389-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/23879279/pubmed\" target=\"_blank\" id=\"23879279\">23879279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sicherer S, Simons F, et al, &ldquo;Self-Injectable Epinephrine for First-Aid Management of Anaphylaxis&rdquo;, <i>Pediatrics</i>, 2007, 119(3):638-46.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FE, Ardusso LR, Bil&ograve; MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. <i>World Allergy Organ J.</i> 2011;4(2):13-37.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smetzer J, Cohen M, eds. Mydriasis indication eliminated from Adrenalin brand. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2017;22(12):1-2.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stiell IG, Hebert PC, Wells GA, et al, &ldquo;Vasopressin Versus Epinephrine for Inhospital Cardiac Arrest: A Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2001, 358(9276):105-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/11463411/pubmed\" target=\"_blank\" id=\"11463411\">11463411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stier PA, Bogner MP, Webster K, et al, &quot;Use of Subcutaneous Terbutaline to Reverse Peripheral Ischemia,&quot; <i>Am J Emerg Med</i>, 1999, 17(1):91-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/9928712/pubmed\" target=\"_blank\" id=\"9928712\">9928712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Symjepi (epinephrine) injection [prescribing information]. San Diego, CA: Adamis Pharmaceuticals; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA. <i>Handbook on Injectable Drugs</i>. 18th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Twinject (epinephrine) [product monograph]. Montreal, QC: Paladin Labs Inc; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/28923988/pubmed\" target=\"_blank\" id=\"28923988\">28923988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waisman Y, Klein BL, Boenning DA, et al, &ldquo;Prospective Randomized Double-Blind Study Comparing L-Epinephrine and Racemic Epinephrine Aerosols in the Treatment of Laryngotracheitis (Croup),&rdquo; <i>Pediatrics</i>, 1992, 89(2):302-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/1734400/pubmed\" target=\"_blank\" id=\"1734400\">1734400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wenzel V, Krismer AC, Arntz HR, et al, &ldquo;A Comparison of Vasopressin and Epinephrine for Out-of-Hospital Cardiopulmonary Resuscitation. European Resuscitation Council Vasopressor during Cardiopulmonary Resuscitation Study Group,&rdquo; <i>N Engl J Med</i>, 2004, 350(2):105-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/14711909/pubmed\" target=\"_blank\" id=\"14711909\">14711909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong AF, McCulloch LM, and Sola A, &ldquo;Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates,&rdquo; <i>J Pediatr</i>, 1992, 121(6):980-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-drug-information/abstract-text/1447671/pubmed\" target=\"_blank\" id=\"1447671\">1447671</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105602 Version 93.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50306669\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45623785\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45623786\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45623791\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F45623834\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45623833\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F45623835\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45623836\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45623837\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45623858\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45623789\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50287478\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45623839\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F45623849\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F45623848\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45623795\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F45623796\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45623780\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45623807\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45623804\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45623805\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45623814\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45623811\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F45623800\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45623801\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45623802\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45623850\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45623822\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45623824\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45623860\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45855086\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/105602|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=epinephrine-adrenaline-systemic-patient-drug-information\" class=\"drug drug_patient\">Epinephrine (adrenaline) (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=epinephrine-adrenaline-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Epinephrine (adrenaline) (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}